Dendritic cell therapy of high-grade gliomas

Brain Pathology

Volumn 19, Issue 4, 2009, Pages 694-712

  Van Gool, Stefaan ^a,b   Maes, Wim ^b   Ardon, Hilko ^c   Verschuere, Tina ^b   Van Cauter, Sofie ^a   De Vleeschouwer, Steven ^c  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c KU LEUVEN UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Clinical trials; Dendritic cells; Glioblastoma; High grade glioma; Immunotherapy; Translational medicine

Indexed keywords

RNA;

ANTIANGIOGENIC ACTIVITY; CANCER GRADING; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURVIVAL; CELL THERAPY; CONFERENCE PAPER; DENDRITIC CELL; EXPERIMENTAL STUDY; GENE THERAPY; GLIOBLASTOMA; GLIOMA; HUMAN; IMMUNIZATION; IMMUNOGENICITY; IMMUNOTHERAPY; INJECTION SITE; LABORATORY TEST; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; TUMOR LOCALIZATION; VACCINATION;

ANIMALS; ANTINEOPLASTIC PROTOCOLS; BRAIN NEOPLASMS; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; GLIOMA; HUMANS; IMMUNOTHERAPY; MICE; TREATMENT OUTCOME;

EID: 69949142058     PISSN: 10156305     EISSN: 17503639     Source Type: Journal    
DOI: 10.1111/j.1750-3639.2009.00316.x     Document Type: Conference Paper

References (149)

1. Aarntzen EH, Figdor CG, Adema GJ, Punt CJ, de Vries IJ (2008) Dendritic cell vaccination and immune monitoring. Cancer Immunol Immunother 57 : 1559 1568.
2. Akasaki Y, Black KL, Yu JS (2005) Dendritic cell-based immunotherapy for malignant gliomas. Expert Rev Neurother 5 : 497 508.
3. Akasaki Y, Black KL, Yu JS (2005) T cell immunity in patients with malignant glioma: recent progress in dendritic cell-based immunotherapeutic approaches. Front Biosci 10 : 2908 2921.
4. Akasaki Y, Liu G, Chung NH, Ehtesham M, Black KL, Yu JS (2004) Induction of a CD4+ T regulatory type 1 response by cyclooxygenase-2-overexpressing glioma. J Immunol 173 : 4352 4359.
5. Aoki H, Mizuno M, Natsume A, Tsugawa T, Tsujimura K, Takahashi T, Yoshida J (2001) Dendritic cells pulsed with tumor extract-cationic liposome complex increase the induction of cytotoxic T lymphocytes in mouse brain tumor. Cancer Immunol Immunother 50 : 463 468.
6. Banchereau J, Palucka AK (2005) Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 5 : 296 306. (Pubitemid 40516155)
7. Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392 : 245 252.
8. Basse PH, Whiteside TL, Chambers W, Herberman RB (2001) Therapeutic activity of NK cells against tumors. Int Rev Immunol 20 : 439 501.
9. Bergwelt-Baildon MS, Popov A, Saric T, Chemnitz J, Classen S, Stoffel MS et al (2006) CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition. Blood 108 : 228 237.
10. Boczkowski D, Nair SK, Snyder D, Gilboa E (1996) Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 184 : 465 472. (Pubitemid 26324100)
11. Boethius J, Blomgren H, Collins VP, Greitz T, Strander H (1983) The effect of systemic human interferon-alpha administration to patients with glioblastoma multiforme. Acta Neurochir (Wien) 68 : 239 251.
12. Bonehill A, Van Nuffel AM, Corthals J, Tuyaerts S, Heirman C, Francois V et al (2009) Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients. Clin Cancer Res 15 : 3366 3375.
13. Brada M, Hoang-Xuan K, Rampling R, Dietrich PY, Dirix LY, Macdonald D et al (2001) Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 12 : 259 266.
14. Burnet NG, Jefferies SJ, Benson RJ, Hunt DP, Treasure FP (2005) Years of life lost (YLL) from cancer is an important measure of population burden - and should be considered when allocating research funds. Br J Cancer 92 : 241 245.
15. Calzascia T, Masson F, Berardino-Besson W, Contassot E, Wilmotte R, Aurrand-Lions M et al (2005) Homing phenotypes of tumor-specific CD8 T cells are predetermined at the tumor site by crosspresenting APCs. Immunity 22 : 175 184.
16. Candolfi M, Curtin JF, Nichols WS, Muhammad AG, King GD, Pluhar GE et al (2007) Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression. J Neurooncol 85 : 133 148.
17. Carpentier AF, Meng Y (2006) Recent advances in immunotherapy for human glioma. Curr Opin Oncol 18 : 631 636.
18. Chi DD, Merchant RE, Rand R, Conrad AJ, Garrison D, Turner R et al (1997) Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas. Am J Pathol 150 : 2143 2152.
19. Ciesielski MJ, Apfel L, Barone TA, Castro CA, Weiss TC, Fenstermaker RA (2006) Antitumor effects of a xenogeneic survivin bone marrow derived dendritic cell vaccine against murine GL261 gliomas. Cancer Immunol Immunother 55 : 1491 1503.
20. Ciesielski MJ, Kozbor D, Castanaro CA, Barone TA, Fenstermaker RA (2008) Therapeutic effect of a T helper cell supported CTL response induced by a survivin peptide vaccine against murine cerebral glioma. Cancer Immunol Immunother 57 : 1827 1835.
21. Claes A, Idema AJ, Wesseling P (2007) Diffuse glioma growth: a guerilla war. Acta Neuropathol 114 : 443 458.
22. Claes A, Schuuring J, Boots-Sprenger S, Hendriks-Cornelissen S, Dekkers M, van der Kogel AJ et al (2008) Phenotypic and genotypic characterization of orthotopic human glioma models and its relevance for the study of anti-glioma therapy. Brain Pathol 18 : 423 433.
23. Clarke SR (2000) The critical role of CD40/CD40L in the CD4-dependent generation of CD8+ T cell immunity. J Leukoc Biol 67 : 607 614.
24. Curran WJ Jr., Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ et al (1993) Recursive partitioning analysis of prognostic factors in three radiation therapy oncology group malignant glioma trials. J Natl Cancer Inst 85 : 704 710.
25. De Vleeschouwer S, Van Calenbergh F, Demaerel P, Flamen P, Rutkowski S, Kaempgen E et al (2004) Transient local response and persistent tumor control of recurrent malignant glioma treated with combination therapy including dendritic cell therapy. J Neurosurg (Pediatrics) 100 : 492 497.
26. De Vleeschouwer S, Arredouani M, Ade M, Cadot P, Vermassen E, Ceuppens JL, Van Gool SW (2005) Uptake and presentation of malignant glioma tumor cell lysates by monocyte-derived dendritic cells. Cancer Immunol Immunother 54 : 372 382.
27. De Vleeschouwer S, Van Gool SW, Van Calenbergh F (2005) Immunotherapy for malignant gliomas: emphasis on strategies of active specific immunotherapy using autologous dendritic cells. Childs Nerv Syst 21 : 7 18.
28. De Vleeschouwer S, Rapp M, Sorg RV, Steiger HJ, Stummer W, Van Gool S, Sabel M (2006) Dendritic cell vaccination in patients with malignant gliomas: current status and future directions. Neurosurgery 59 : 988 999.
29. De Vleeschouwer S, Spencer Lopes I, Ceuppens JL, Van Gool SW (2007) Persistent IL-10 production is required for glioma growth suppressive activity by Th1-directed effector cells after stimulation with tumor lysate-loaded dendritic cells. J Neurooncol 84 : 131 140.
30. De Vleeschouwer S, Fieuws S, Rutkowski S, Van Calenbergh F, Van Loon J, Goffin J et al (2008) Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res 14 : 3098 3104.
31. Dhodapkar KM, Cirignano B, Chamian F, Zagzag D, Miller DC, Finlay JL, Steinman RM (2004) Invariant natural killer T cells are preserved in patients with glioma and exhibit antitumor lytic activity following dendritic cell-mediated expansion. Int J Cancer 109 : 893 899.
32. Di CA, Scarabino T, Trojsi F, Popolizio T, Catapano D, Giannatempo GM et al (2008) Proton MR spectroscopy of cerebral gliomas at 3 T: spatial heterogeneity, and tumour grade and extent. Eur Radiol 18 : 1727 1735.
33. Dix AR, Brooks WH, Roszman TL, Morford LA (1999) Immune defects observed in patients with primary malignant brain tumors. J Neuroimmunol 100 : 216 232.
34. Dredge K, Marriott JB, Todryk SM, Dalgleish AG (2002) Adjuvants and the promotion of Th1-type cytokines in tumour immunotherapy. Cancer Immunol Immunother 51 : 521 531.
35. Dunn GP, Dunn IF, Curry WT (2007) Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human glioma. Cancer Immun 7 : 12.
36. Elliott LH, Brooks WH, Roszman TL (1987) Activation of immunoregulatory lymphocytes obtained from patients with malignant gliomas. J Neurosurg 67 : 231 236.
37. Erdmann M, Dorrie J, Schaft N, Strasser E, Hendelmeier M, Kaempgen E et al (2007) Effective clinical-scale production of dendritic cell vaccines by monocyte elutriation directly in medium, subsequent culture in bags and final antigen loading using peptides or RNA transfection. J Immunother 30 : 663 674.
38. Everson RG, Graner MW, Gromeier M, Vredenburgh JJ, Desjardins A, Reardon DA et al (2008) Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma. Expert Rev Anticancer Ther 8 : 717 732.
39. Farkkila M, Jaaskelainen J, Kallio MJ, Blomstedt G, Raininko R, Virkkunen P et al (1994) Randomised, controlled study of intratumoral recombinant gamma-interferon treatment in newly diagnosed glioblastoma. Br J Cancer 70 : 138 141.
40. Fecci PE, Sweeney AE, Grossi PM, Nair SK, Learn CA, Mitchell DA et al (2006) Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells. Clin Cancer Res 12 : 4294 4305.
41. Fenstermaker RA, Ciesielski MJ (2004) Immunotherapeutic strategies for malignant glioma. Cancer Control 11 : 181 191.
42. Fleury A, Menegoz F, Grosclaude P, Daures JP, Henry Amar M, Raverdy N et al (1997) Descriptive epidemiology of cerebral gliomas in France. Cancer 79 : 1195 1202.
43. Fomchenko EI, Holland EC (2006) Mouse models of brain tumors and their applications in preclinical trials. Clin Cancer Res 12 : 5288 5297.
44. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A et al (2007) Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 21 : 2683 2710.
45. Gabrilovich DI (2002) Dendritic cell vaccines for cancer treatment. Curr Opin Mol Ther 4 : 452 458.
46. Gerstner ER, Duda DG, di Tomaso E, Sorensen G, Jain RK, Batchelor TT (2007) Antiangiogenic agents for the treatment of glioblastoma. Expert Opin Investig Drugs 16 : 1895 1908.
47. Gilboa E, Vieweg J (2004) Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol Rev 199 : 251 263.
48. Gilboa E, Nair SK, Lyerly HK (1998) Immunotherapy of cancer with dendritic-cell-based vaccines. Cancer Immunol Immunother 46 : 82 87.
49. Graf MR, Sauer JT, Merchant RE (2005) Tumor infiltration by myeloid suppressor cells in response to T cell activation in rat gliomas. J Neurooncol 73 : 29 36.
50. Grauer OM, Nierkens S, Bennink E, Toonen LW, Boon L, Wesseling P et al (2007) CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo. Int J Cancer 121 : 95 105.
51. Grauer OM, Sutmuller RP, van Maren W, Jacobs JF, Bennink E, Toonen LW et al (2008) Elimination of regulatory T cells is essential for an effective vaccination with tumor lysate-pulsed dendritic cells in a murine glioma model. Int J Cancer 122 : 1794 1802.
52. Gruber S, Stadlbauer A, Mlynarik V, Gatterbauer B, Roessler K, Moser E (2005) Proton magnetic resonance spectroscopic imaging in brain tumor diagnosis. Neurosurg Clin N Am 16 : 101 114, vi.
53. Grunebach F, Muller MR, Nencioni A, Brossart P (2003) Delivery of tumor-derived RNA for the induction of cytotoxic T-lymphocytes. Gene Ther 10 : 367 374.
54. Heath WR, Carbone FR (2001) Cross-presentation, dendritic cells, tolerance and immunity. Annu Rev Immunol 19 : 47 64.
55. Hirai T, Murakami R, Nakamura H, Kitajima M, Fukuoka H, Sasao A et al (2008) Prognostic value of perfusion MR imaging of high-grade astrocytomas: long-term follow-up study. AJNR Am J Neuroradiol 29 : 1505 1510.
56. Hoos A, Parmiani G, Hege K, Sznol M, Loibner H, Eggermont A et al (2007) A clinical development paradigm for cancer vaccines and related biologics. J Immunother 30 : 1 15.
57. Imaizumi T, Kuramoto T, Matsunaga K, Shichijo S, Yutani S, Shigemori M et al (1999) Expression of the tumor-rejection antigen SART1 in brain tumors. Int J Cancer 83 : 760 764.
58. Insug O, Ku G, Ertl HC, Blaszczyk-Thurin M (2002) A dendritic cell vaccine induces protective immunity to intracranial growth of glioma. Anticancer Res 22 : 613 321.
59. Jefford M, Maraskovsky E, Cebon J, Davis ID (2001) The use of dendritic cells in cancer therapy. Lancet Oncol 2 : 343 353.
60. Jonuleit H, Kuhn U, Muller G, Steinbrink K, Paragnik L, Schmitt E et al (1997) Proinflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal-calf serum-free conditions. Eur J Immunol 27 : 3135 3142.
61. Jouanneau E, Poujol D, Gulia S, Le Mercier I, Blay JY, Belin MF, Puisieux I (2005) Dendritic cells are essential for priming but inefficient for boosting antitumour immune response in an orthotopic murine glioma model. Cancer Immunol Immunother 55 : 1 14.
62. Kalinski P, Hilkens CMU, Wierenga EA, Kapsenberg ML (1999) T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunol Today 20 : 561 567.
63. Khan JA, Yaqin S (2006) Dendritic cell therapy with improved outcome in glioma multiforme - a case report. J Zhejiang Univ Sci B 7 : 114 117.
64. Kikuchi T, Akasaki Y, Irie M, Homma S, Abe T, Ohno T (2001) Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol Immunother 50 : 337 344.
65. Kikuchi T, Akasaki Y, Abe T, Fukuda T, Saotome H, Ryan JL et al (2004) Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. J Immunother 27 : 452 459.
66. Kjaergaard J, Tanaka J, Kim JA, Rothchild K, Weinberg A, Shu S (2000) Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth. Cancer Res 60 : 5514 5521.
67. Kjaergaard J, Wang LX, Kuriyama H, Shu S, Plautz GE (2005) Active immunotherapy for advanced intracranial murine tumors by using dendritic cell-tumor cell fusion vaccines. J Neurosurg 103 : 156 164.
68. Kleihues P, Soylemezoglu F, Schauble B, Scheithauer BW, Burger PC (1995) Histopathology, classification, and grading of gliomas. Glia 15 : 211 221.
69. Kurpad SN, Zhao XG, Wikstrand CJ, Batra SK, McLendon RE, Bigner DD (1995) Tumor antigens in astrocytic gliomas. Glia 15 : 244 256.
70. Kuwashima N, Nishimura F, Eguchi J, Sato H, Hatano M, Tsugawa T et al (2005) Delivery of dendritic cells engineered to secrete IFN-alpha into central nervous system tumors enhances the efficacy of peripheral tumor cell vaccines: dependence on apoptotic pathways. J Immunol 175 : 2730 2740.
71. Lesterhuis WJ, Aarntzen EH, De Vries IJ, Schuurhuis DH, Figdor CG, Adema GJ, Punt CJ (2008) Dendritic cell vaccines in melanoma: from promise to proof? Crit Rev Oncol Hematol 66 : 118 134.
72. Levitsky HI, Lazenby A, Hayashi RJ, Pardoll DM (1994) In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression. J Exp Med 179 : 1215 1224.
73. Liau LM, Black KL, Martin NA, Sykes SN, Bronstein JM, Jouben-Steele L et al (2000) Treatment of a glioblastoma patient by vaccination with autologous dendritic cells pulsed with allogeneic Major Histocompatibility Complex Class I-matched tumor peptides: case report. Neurosurgical Focus 9 : e8.
74. Liau LM, Prins RM, Kiertscher SM, Odesa SK, Kremen TJ, Giovannone AJ et al (2005) Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 11 : 5515 5525.
75. Liu G, Khong HT, Wheeler CJ, Yu JS, Black KL, Ying H (2003) Molecular and functional analysis of tyrosinase-related protein (TRP)-2 as a cytotoxic T lymphocyte target in patients with malignant glioma. J Immunother 26 : 301 312.
76. Liu G, Ying H, Zeng G, Wheeler CJ, Black KL, Yu JS (2004) HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells. Cancer Res 64 : 4980 4986.
77. Liu G, Yu JS, Zeng G, Yin D, Xie D, Black KL, Ying H (2004) AIM-2: a novel tumor antigen is expressed and presented by human glioma cells. J Immunother 27 : 220 226.
78. Lumniczky K, Desaknai S, Mangel L, Szende B, Hamada H, Hidvegi EJ, Safrany G (2002) Local tumor irradiation augments the antitumor effect of cytokine-producing autologous cancer cell vaccines in a murine glioma model. Cancer Gene Ther 9 : 44 52.
79. Luptrawan A, Liu G, Yu JS (2008) Dendritic cell immunotherapy for malignant gliomas. Rev Recent Clin Trials 3 : 10 21.
80. Macdonald DR, Cascino TL, Schold SC Jr., Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8 : 1277 1280.
81. Maes W, Galicia Rosas G, Verbinnen B, Boon L, De Vleeschouwer S, Ceuppens JL, Van Gool SW (2008) DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma. Neurooncol 2009 Mar 31. [Epub ahead of print].
82. Maes W, Deroose C, Reumers V, Krylyshkina O, Gijsbers R, Ceuppens J et al (2009) In vivo bioluminescence imaging in an experimental mouse model for dendritic cell based immunotherapy against malignant glioma. J Neurooncol 91 : 127 139.
83. Maldonado-Lopez R, Moser M (2001) Dendritic cell subsets and the regulation of Th1/Th2 responses. Semin Immunol 13 : 275 282.
84. Mason WP (2008) Emerging drugs for malignant glioma. Expert Opin Emerg Drugs 13 : 81 94.
85. McLendon RE, Wikstrand CJ, Matthews MR, Al-Baradei R, Bigner SH, Bigner DD (2000) Glioma-associated antigen expression in oligodendroglial neoplasms. Tenascin and epidermal growth factor receptor. J Histochem Cytochem 48 : 1103 1110.
86. Merchant RE, McVicar DW, Merchant LH, Young HF (1992) Treatment of recurrent malignant glioma by repeated intracerebral injections of human recombinant interleukin-2 alone or in combination with systemic interferon-alpha. Results of a phase I clinical trial. J Neurooncol 12 : 75 83.
87. Moser M (2003) Dendritic cells in immunity and tolerance - do they display opposite functions? Immunity 19 : 5 8.
88. Nair S, McLaughlin C, Weizer A, Su Z, Boczkowski D, Dannull J et al (2003) Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation. J Immunol 171 : 6275 6282.
89. Ni HT, Spellman SR, Jean WC, Hall WA, Low WC (2001) Immunization with dendritic cells pulsed with tumor extract increases survival of mice bearing intracranial gliomas. J Neurooncol 51 : 1 9.
90. Nieder C, Grosu AL, Molls M (2000) A comparison of treatment results for recurrent malignant gliomas. Cancer Treat Rev 26 : 397 409.
91. Oh J, Henry RG, Pirzkall A, Lu Y, Li X, Catalaa I et al (2004) Survival analysis in patients with glioblastoma multiforme: predictive value of choline-to-N-acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume. J Magn Reson Imaging 19 : 546 554.
92. Okada H, Lieberman FS, Walter KA, Lunsford LD, Kondziolka DS, Bejjani GK et al (2007) Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas. J Transl Med 5 : 67.
93. Okano F, Storkus WJ, Chambers WH, Pollack IF, Okada H (2002) Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain. Clin Cancer Res 8 : 2851 2855.
94. Parajuli P, Sloan AE (2004) Dendritic cell-based immunotherapy of malignant gliomas. Cancer Invest 22 : 405 416.
95. Parajuli P, Mathupala S, Sloan AE (2004) Systematic comparison of dendritic cell-based immunotherapeutic strategies for malignant gliomas: in vitro induction of cytolytic and natural killer-like T cells. Neurosurgery 55 : 1194 1204.
96. Parajuli P, Mathupala S, Mittal S, Sloan AE (2007) Dendritic cell-based active specific immunotherapy for malignant glioma. Expert Opin Biol Ther 7 : 439 448.
97. Parney IF, Hao C, Petruk KC (2000) Glioma immunology and immunotherapy. Neurosurgery 46 : 778 791.
98. Pellegatta S, Poliani PL, Corno D, Grisoli M, Cusimano M, Ubiali F et al (2006) Dendritic cells pulsed with glioma lysates induce immunity against syngeneic intracranial gliomas and increase survival of tumor-bearing mice. Neurol Res 28 : 527 531.
99. Pellegatta S, Poliani PL, Corno D, Menghi F, Ghielmetti F, Suarez-Merino B et al (2006) Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas. Cancer Res 66 : 10247 10252.
100. Plautz GE, Yang ZY, Wu BY, Gao X, Huang L, Nabel GJ (1993) Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc Natl Acad Sci USA 90 : 4645 4649.
101. Price SJ, Jena R, Burnet NG, Carpenter TA, Pickard JD, Gillard JH (2007) Predicting patterns of glioma recurrence using diffusion tensor imaging. Eur Radiol 17 : 1675 1684.
102. Prins RM, Liau LM (2004) Cellular immunity and immunotherapy of brain tumors. Front Biosci 9 : 3124 3136.
103. Prins RM, Scott GP, Merchant RE, Graf MR (2002) Irradiated tumor cell vaccine for treatment of an established glioma. II. Expansion of myeloid suppressor cells that promote tumor progression. Cancer Immunol Immunother 51 : 190 199.
104. Prins RM, Craft N, Bruhn KW, Khan-Farooqi H, Koya RC, Stripecke R et al (2006) The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity. J Immunol 176 : 157 164.
105. Provenzale JM, Mukundan S, Barboriak DP (2006) Diffusion-weighted and perfusion MR imaging for brain tumor characterization and assessment of treatment response. Radiology 239 : 632 649.
106. Quattrocchi KB, Miller CH, Cush S, Bernard SA, Dull ST, Smith M et al (1999) Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas. J Neurooncol 45 : 141 157.
107. Rapp M, Ozcan Z, Steiger HJ, Wernet P, Sabel MC, Sorg RV (2006) Cellular immunity of patients with malignant glioma: prerequisites for dendritic cell vaccination immunotherapy. J Neurosurg 105 : 41 50.
108. Rechtsteiner G, Warger T, Osterloh P, Schild H, Radsak MP (2005) Cutting edge: priming of CTL by transcutaneous peptide immunization with imiquimod. J Immunol 174 : 2476 2480.
109. Rock KL, Clark K (1996) Analysis of the role of MHC class II presentation in the stimulation of cytotoxic T lymphocytes by antigens targeted into the exogenous antigen-MHC class I presentation pathway. J Immunol 156 : 3721 3726.
110. Rock KL, Gamble S, Rothstein L (1990) Presentation of exogenous antigen with class I major histocompatibility complex molecules. Science 249 : 918 921.
111. Rutkowski S, De Vleeschouwer S, Kaempgen E, Wolff JEA, Kuhl J, Demaerel P et al (2004) Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study. Br J Cancer 91 : 1656 1662.
112. Saito R, Mizuno M, Nakahara N, Tsuno T, Kumabe T, Yoshimoto T, Yoshida J (2004) Vaccination with tumor cell lysate-pulsed dendritic cells augments the effect of IFN-beta gene therapy for malignant glioma in an experimental mouse intracranial glioma. Int J Cancer 111 : 777 782.
113. Saris SC, Spiess P, Lieberman DM, Lin S, Walbridge S, Oldfield EH (1992) Treatment of murine primary brain tumors with systemic interleukin-2 and tumor-infiltrating lymphocytes. J Neurosurg 76 : 513 519.
114. Scandella E, Men Y, Gillessen S, Forster R, Groettrup M (2002) Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. Blood 100 : 1354 1361.
115. Scarcella DL, Chow CW, Gonzales MF, Economou C, Brasseur F, Ashley DM (1999) Expression of MAGE and GAGE in high-grade brain tumors: a potential target for specific immunotherapy and diagnostic markers. Clin Cancer Res 5 : 335 341.
116. Sikorski CW, Lesniak MS (2005) Immunotherapy for malignant glioma: current approaches and future directions. Neurol Res 27 : 703 716.
117. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoom MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Eng J Med 352 : 987 996.
118. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10 : 459 466.
119. Svane IM, Soot ML, Buus S, Johnsen HE (2003) Clinical application of dendritic cells in cancer vaccination therapy. APMIS 111 : 818 834.
120. Tamber MS, Rutka JT (2003) Pediatric supratentorial high-grade gliomas. Neurosurg Focus 14 : e1.
121. Tanaka H, Shimizu K, Hayashi T, Shu S (2002) Therapeutic immune response induced by electrofusion of dendritic and tumor cells. Cell Immunol 220 : 1 12.
122. Tang J, Flomenberg P, Harshyne L, Kenyon L, Andrews DW (2005) Glioblastoma patients exhibit circulating tumor-specific CD8+ T cells. Clin Cancer Res 11 : 5292 5299.
123. Tsugawa T, Kuwashima N, Sato H, Fellows-Mayle WK, Dusak JE, Okada K et al (2004) Sequential delivery of interferon-alpha gene and DCs to intracranial gliomas promotes an effective antitumor response. Gene Ther 11 : 1551 1558.
124. Tuyaerts S, Aerts JL, Corthals J, Neyns B, Heirman C, Breckpot K et al (2007) Current approaches in dendritic cell generation and future implications for cancer immunotherapy. Cancer Immunol Immunother 56 : 1513 1537.
125. Umemura N, Saio M, Suwa T, Kitoh Y, Bai J, Nonaka K et al (2008) Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type characteristics. J Leukoc Biol 83 : 1136 1144.
126. Van Gool SW, Van den Hove L, Ceuppens JL (2000) Activation of the immune system in cancer patients. Med Pediatr Oncol 34 : 1 9.
127. Van Gool SW, Vandenberghe P, de Boer M, Ceuppens JL (1996) CD80, CD86 and CD40 provide accessory signals in a multiple step T cell activation model. Immunol Rev 153 : 47 83.
128. Ventimiglia JB, Wikstrand CJ, Ostrowski LE, Bourdon MA, Lightner VA, Bigner DD (1992) Tenascin expression in human glioma cell lines and normal tissues. J Neuroimmunol 36 : 41 55.
129. Verdijk P, Aarntzen EH, Lesterhuis WJ, Boullart AC, Kok E, van Rossum MM et al (2009) Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients. Clin Cancer Res 15 : 2531 2540.
130. Walker DG, Laherty R, Tomlinson FH, Chuah T, Schmidt C (2008) Results of a phase I dendritic cell vaccine trial for malignant astrocytoma: potential interaction with adjuvant chemotherapy. J Clin Neurosci 15 : 114 121.
131. Weaver CT, Harrington LE, Mangan PR, Gavrieli M, Murphy KM (2006) Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 24 : 677 688.
132. Wersall P, Ohlsson I, Biberfeld P, Collins VP, von Krusenstjerna S, Larsson S et al (1997) Intratumoral infusion of the monoclonal antibody, mAb 425, against the epidermal-growth-factor receptor in patients with advanced malignant glioma. Cancer Immunol Immunother 44 : 157 164.
133. Wheeler CJ, Black KL (2005) Dendritic cell vaccines and immunity in glioma patients. Front Biosci 10 : 2861 2881.
134. Wheeler CJ, Black KL, Liu G, Mazer M, Zhang XX, Pepkowitz S et al (2008) Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res 68 : 5955 5964.
135. Wheeler CJ, Black KL, Liu G, Ying H, Yu JS, Zhang W, Lee PK (2003) Thymic CD8(+) T cell production strongly influences tumor antigen recognition and age-dependent glioma mortality. J Immunol 171 : 4927 4933.
136. Whiteside TL, Odoux C (2004) Dendritic cell biology and cancer therapy. Cancer Immunol Immunother 53 : 240 248.
137. Wolff JE, Classen CF, Wagner S, Kortmann RD, Palla SL, Pietsch T et al (2008) Subpopulations of malignant gliomas in pediatric patients: analysis of the HIT-GBM database. J Neurooncol 87 : 155 164.
138. Wu AH, Xiao J, Anker L, Hall WA, Gregerson DS, Cavenee WK et al (2005) Identification of EGFRvIII-derived CTL epitopes restricted by HLA A0201 for dendritic cell based immunotherapy of gliomas. J Neurooncol 76 : 23 30.
139. Yamada Y, Kiroiwa T, Nakagawa T, Kajimoto Y, Dohi T, Azuma H et al (2003) Transcriptional expression of survivin and its splice variants in brain tumors in humans. J Neurosurg 99 : 338 345.
140. Yamanaka R (2006) Novel immunotherapeutic approaches to glioma. Curr Opin Mol Ther 8 : 46 51.
141. Yamanaka R (2008) Cell- and peptide-based immunotherapeutic approaches for glioma. Trends Mol Med 14 : 228 235.
142. Yamanaka R, Abe T, Yajima N, Tsuchiya N, Homma J, Kobayashi T et al (2003) Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial. Br J Cancer 89 : 1172 1179.
143. Yamanaka R, Homma J, Yajima N, Tsuchiya N, Sano M, Kobayashi T et al (2005) Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res 11 : 4160 4167.
144. Yamanaka R, Yajima N, Abe T, Tsuchiya N, Homma J, Narita N et al (2003) Dendritic cell-based glioma immunotherapy. Int J Oncol 23 : 5 15.
145. Yoshida J, Wakabayashi T, Mizuno M, Sugita K, Yoshida T, Hori S et al (1992) Clinical effect of intra-arterial tumor necrosis factor-alpha for malignant glioma. J Neurosurg 77 : 78 83.
146. Yu JS, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ (2004) Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 64 : 4973 4979.
147. Yu JS, Wheeler CJ, Zeltzer PM, Ying H, Finger DN, Lee PK et al (2001) Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 61 : 842 847.
148. Yung WK, Prados M, Levin VA, Fetell MR, Bennett J, Mahaley MS et al (1991) Intravenous recombinant interferon beta in patients with recurrent malignant gliomas: a phase I/II study. J Clin Oncol 9 : 1945 1949.
149. Zeltzer PM, Moilanen B, Yu JS, Black KL (1999) Immunotherapy of malignant brain tumors in children and adults: from theoretical principles to clinical application. Childs Nerv Syst 15 : 514 528.